U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110233) titled 'Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma' on July 31.
Brief Summary: This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere(R)) for Hepatocellular Carcinoma (HCC) participants with unresectable Barcelona clinic liver cancer (BCLC) stage A disease.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Hepatocellular Cancer
Hepatocellular Carcinoma Non-resectable
Intervention:
DEVICE: TheraSphere(R) Yttrium-90 microsph...